Co-Diagnostics (NASDAQ:CODX) is up 119% premarket, on announcingfavorable results of a study to detect cancer mutations using its CoPrimer technology, with applications in liquid biopsy and companion diagnostic tests.
The study demonstrated highly specific detection of the ten mutations associated with non-small cell lung cancer (NSCLC), thereby distinguishing the genes with mutations from those without.
The CoPrimer-based polymerase chain reaction test was also shown to be highly sensitive, identifying the NSCLC genes at the lowest possible percentage.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.